The first ‘Collaborative Learning Exchange’ is: “Understanding Mechanisms of Action and Utility of Novel Treatments for Hemophilia A and B.”
This activity will be held live on Wednesday, April 6th from 3:00-4:00 pm EDT
2:00-3:00 pm CDT/ 1:00-2:00 pm MDT/ 12:00 -1:00 pm PDT
Learning Objectives for the live activity include:
- Discuss the mechanisms of action for FVIIIa mimetic bispecific antibodies and anti-tissue factor pathway inhibitor (anti-TPFI) therapies for hemophilia.
- Describe the current and emerging novel non-factor therapy approaches in development for treating patients with hemophilia A and B.
- Summarize the latest clinical trial data available on new and emerging non-factor therapies
- Discuss the potential advantages and challenges to use of non-factor therapies for hemophilia patients
- Collaborate within the healthcare team for shared patient-centered and population focused problem solving for those experiencing bleeding disorders as derived from discussion based treatment strategies and evidence based practice.
Presenters:
Alice Ma, MD, FACP
Professor of Medicine, Department of Medicine,
University of North Carolina at Chapel Hill
Mark Reding, MD
Professor of Medicine, Division of Hematology, Oncology and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
This will be a live, virtual event where attendees will have the opportunity to participate and interact with their peers in smaller breakout rooms immediately following the talks. And there will be a final concluding wrap-up.
Following the program, a resource flyer will be developed and shared to support the learnings from the informational session, case studies, and lessons learned.
“Understanding Mechanisms of Action and Utility of Novel Treatments for Hemophilia A and B" will be held on April 6th, from 3pm to 4pm EST.
ACCREDITED CONTINUING EDUCATION
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and National Hemophilia Foundation. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS
The University of Nebraska Medical Center designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
PHYSICIAN ASSISTANTS
University of Nebraska Medical Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
These trainings are supported by a Cooperative Agreement [Number NU01DD000006], funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.